Data Insights

Surufatinib by Hutchison MediPharma for Fallopian Tube Cancer: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Fallopian Tube Cancer

Data Insights

Surufatinib by Hutchison MediPharma for Metastatic Biliary Tract Cancer: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Metastatic Biliary Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Metastatic Biliary Tract Cancer

Data Insights

Surufatinib by Hutchison MediPharma for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase III for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Pancreatic Ductal Adenocarcinoma

Data Insights

Surufatinib by Hutchison MediPharma for Metastatic Pancreatic Cancer: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase III for Metastatic Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Metastatic Pancreatic Cancer

Data Insights

Surufatinib by Hutchison MediPharma for Ovarian Cancer: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Ovarian Cancer

Data Insights

Surufatinib by Hutchison MediPharma for Soft Tissue Sarcoma: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Soft Tissue Sarcoma

Data Insights

Surufatinib by Hutchison MediPharma for Solid Tumor: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Solid Tumor

Data Insights

Surufatinib by Hutchison MediPharma for Non-Rhabdomyosarcoma: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Non-Rhabdomyosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Non-Rhabdomyosarcoma

Data Insights

Surufatinib by Hutchison MediPharma for Rhabdomyosarcoma: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Rhabdomyosarcoma

Data Insights

Surufatinib by Hutchison MediPharma for Ewing Sarcoma: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Ewing Sarcoma

Data Insights

Surufatinib by Hutchison MediPharma for Osteosarcoma: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Osteosarcoma

Data Insights

Surufatinib by Hutchison MediPharma for Lymphoma: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Lymphoma

Data Insights

Surufatinib by Hutchison MediPharma for Peritoneal Cancer: Likelihood of Approval

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Peritoneal Cancer